NCT07213804 2026-04-17
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
63 trialsNCT06915025 2026-04-13
OVATION-3
Imunon
Phase 3 Recruiting
NCT04498117 2026-04-01
FLORA-5
CanariaBio Inc.
Phase 3 Active not recruiting
NCT04095364 2026-03-24
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT02446600 2026-03-05
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00565851 2025-12-30
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06476184 2025-12-05
SALVOVAR
ARCAGY/ GINECO GROUP
Phase 3 Recruiting
NCT01081262 2025-11-25
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03740165 2025-10-22
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05009082 2025-09-10
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
AGO Study Group
Phase 3 Recruiting
NCT02470585 2024-10-26
VELIA
AbbVie
Phase 3 Terminated
NCT03635489 2024-10-03
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03598270 2024-08-30
ANITA
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT00657878 2023-11-13
MITO-8
National Cancer Institute, Naples
Phase 3 Unknown
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT02429687 2023-04-25
MOGCT-01
Shandong University
Phase 3 Recruiting
NCT02429700 2023-04-25
SCST-01
Shandong University
Phase 3 Recruiting
NCT00326456 2023-03-27
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
National Cancer Institute, Naples
Phase 3 Unknown
NCT00660842 2023-03-24
MITO-7
National Cancer Institute, Naples
Phase 3 Unknown
NCT01802749 2023-03-24
MITO16MANGO2b
National Cancer Institute, Naples
Phase 3 Unknown
NCT03038100 2023-02-17
IMagyn050
Hoffmann-La Roche
Phase 3 Completed
NCT00849667 2022-12-30
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Morphotek
Phase 3 Terminated
NCT04520074 2022-07-27
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Fudan University
Phase 3 Recruiting
NCT01462890 2022-07-20
BOOST
AGO Study Group
Phase 3 Completed
NCT03690739 2022-02-24
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
AGO Research GmbH
Phase 3 Terminated
NCT01379989 2022-02-09
INOVATYON
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT00954174 2021-09-30
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 3 Unknown
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT03806049 2021-07-15
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Withdrawn
NCT01837251 2021-07-13
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
AGO Research GmbH
Phase 3 Completed
NCT02718417 2020-07-14
JAVELIN OVARIAN 100
Pfizer
Phase 3 Terminated
NCT00028743 2020-04-02
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT03693248 2019-12-10
ROCOCO
Seoul National University Hospital
Phase 3 Unknown
NCT00262847 2019-07-23
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003644 2019-06-04
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
GOG Foundation
Phase 3 Completed
NCT00003214 2019-05-15
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
Swiss Cancer Institute
Phase 3 Completed
NCT00011986 2019-04-16
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 3 Completed
NCT01015118 2017-12-07
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT00434642 2017-08-09
OCEANS
Genentech, Inc.
Phase 3 Completed
NCT01493505 2017-02-23
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Amgen
Phase 3 Terminated
NCT02311907 2017-02-23
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00382811 2016-07-18
OVATURE
MEI Pharma, Inc.
Phase 3 Completed
NCT01239732 2016-06-10
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00006453 2015-12-23
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
AGO Study Group
Phase 3 Completed
NCT00006454 2015-12-23
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
AGO Study Group
Phase 3 Completed
NCT00043082 2015-10-26
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00003636 2015-08-05
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00189553 2014-01-10
CALYPSO
ARCAGY/ GINECO GROUP
Phase 3 Completed